Catalyst Wire Dossier Catalyst Wire Dossier

AZD3470

PRMT5 inhibitor · AstraZeneca
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AZD3470, covering 2026-03-06 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. [Phase 1, Phase 2]

See pricing